Presentation is loading. Please wait.

Presentation is loading. Please wait.

Presented by Faten farid elsayed Nutritional Management of Hepatic patients.

Similar presentations

Presentation on theme: "Presented by Faten farid elsayed Nutritional Management of Hepatic patients."— Presentation transcript:

1 Presented by Faten farid elsayed Nutritional Management of Hepatic patients

2 Points will be covered Background on Liver Dysfunction Review of liver physiology Diseases of the liver Acute hepatic failure Chronic liver disease Historical Treatment Theories/Practice Protein Restriction & BCAA Supplementation Goals of MNT

3 Lets Take It From The Top A Physiology Review

4 Functions of the Liver: A Brief Overview Largest organ in body, integral to most metabolic functions of body, performing over 500 tasks Only 10-20% of functioning liver is required to sustain life Removal of liver will result in death within 24 hours

5 Functions of the Liver Main functions include: Metabolism of CHO, protein, fat Storage/activation vitamins and minerals Formation/excretion of bile Steroid metabolism, detoxifier of drugs/alcohol Action as (bacteria) filter and fluid chamber Conversion of ammonia to urea Gastrointestinal tract significant source of ammonia Generated from ingested protein substances that are deaminated by colonic bacteria Ammonia enters circulation via portal vein Converted to urea by liver for excretion

6 Alanine Transaminase (ALT) Aspartate Transaminase(AST) The Urea Cycle

7 Liver Diseases Duration Acute vs Chronic Pathophysiology Hepatocellular vs Cholestasic Etiology Viral Alcohol Toxin Autoimmune Stage/Severity ESLD Cirrhosis Viral hepatitis A, B, C, D, E (and G) Fulminant hepatitis Alcoholic liver disease Non-alcoholic liver disease Cholestatic liver disease Hepatocellular carcinoma Inherited disorders Classifications

8 Progression of Liver Diseases

9 Metabolic change in acute liver failure These patients with hepatic failure have metabolic response = Failing liver +stress response of critical ill patient Nutritional support may aid in regeneration or wait for transplantation These patients with hepatic failure have metabolic response = Failing liver +stress response of critical ill patient Nutritional support may aid in regeneration or wait for transplantation

10 Metabolic change……….. continued Increased resting energy expenditure by % Energy expenditure 1- decrese insulin sensitivity as glucagon secretion increased 2- glucagon not suppressed by glucose infusion Glucose metabolism Decreased hepatic ketogenesis low conc of free fatty acids and ketone bodies However they tolerate intravenous lipid emlusion contain (MCT/LCT) Lipid metabolism Increased its level 3 to 4 folds Decreased( BCCA) and increased (Tryptophan, AAA and sulphur containing AA No elemination of AA in splanchnic area Increased rate of conversion of glutamine to ammonia +alanine More glutamine production in brain and skeletal muscle No urea formation Plasma amino acids

11 Treatment of ALF Various measures in current treatment of ALF Strategies to lower ammonia production/absorption Nutritional management Protein restriction BCAA supplementation Medical management Medications to counteract ammonias effect on brain cell function Lactulose Antibiotics Devices to compensate for liver dysfunction Liver transplantation

12 Proposed Complex Feedback Mechanisms In Treatment Of HE

13 Nutrition requirement in ALF

14 Patient with ALF have glucose intolerance Hyperammonia Increased REE Malnourished patients: begin nutrition at reduced calorie levels Caloric requirement -Potien requirement----- discussed below Carbohdrate and lipid to supply calories Minerals and vitamines should be supplied Substrate requirements -oral feeding -if patient not tolerate oral; entral is recommended to ensure adequate intake of calories Route of nutrition feeding

15 Nutritional Management of ALF Historical treatment theories Protein Restriction BCAA supplementation

16 Historical Treatment Theories:Protein Restriction Studies in early 1950s showed cirrhotic pts given nitrogenous substances developed hepatic precoma Led to introduction of protein restriction Began with 20-40g protein/day regardless body weight Increased by 10g increments q3-5 days as tolerated with clinical recovery Upper limit of g/kg Was thought sufficient to achieve positive nitrogen balance Lack of Valid Evidence Efficacy of restriction never proven within controlled trial

17 Protein restriction?? Normal Protein Diet for Episodic Hepatic Encephalopathy Cordoba et al. J Hepatol 2004; 41: Objective: To test safety of normal-protein diets Randomized, controlled trial in 20 cirrhotic patients with HE 10 patients subjected to protein restriction, followed by progressive increments No protein first 3 days, increasing q3days until 1.2g/kg daily for last 2 days 10 patients followed normal protein diet (1.2g/kg) Both groups received equal calories

18 Protein restriction?? Results On days 2 and 14: Similar protein synthesis among both groups Protein breakdown higher in low-protein group Conclusion No significant differences in course of hepatic encephalopathy Greater protein breakdown in protein-restricted subjects

19 Protein and HE Considerations No valid clinical evidence supporting protein restriction in pts with acute ALF Protein intake < 40g/day contributes to malnutrition and worsening ALF Increased endogenous protein breakdown NH3 Susceptibiliy to infection increases under such catabolic conditions

20 BCAA Supplementation Effective or Not?

21 Branched Chain Amino Acids (BCAA) Valine Leucine Isoleucine Important fuel sources for skeletal muscle during periods of metabolic stress Metabolized in muscle & brain, not liver -promote protein synthesis -suppress protein catabolism -substrates for gluconeogenesis Catabolized to L-alanine and L- glutamine in skeletal muscle

22 Branched-Chain Amino Acids For Hepatic Encephalopathy Als-Nielsen B, Koretz RI, Kjaergard LL, Gluud C. The Cochrane Database of Systematic Reviews, 2003, 1-55

23 Branched-Chain Amino Acids For Hepatic Encephalopathy Meta-Analysis of randomized-controlled trials on the treatment of HE with IV or oral BCAA Objective To evaluate the beneficial and harmful effects of BCAA or BCAA-enriched interventions for patients with hepatic encepalopathy Review Criteria All randomized trials included, irrespective of blinding, publication status, or language Data from first period of crossover trials and unpublished trials included if methodology and data accessible Participants Patients with HE in connection with acute or chronic liver disease or FHF Patients of either gender, any age and ethnicity included irrespective of etiology of liver disease or precipitating factors of HE

24 Branched-Chain Amino Acids For Hepatic Encephalopathy Types of Interventions Experimental Group BCAA or BCAA-enriched solutions given in any mode, dose, or duration with or without other nutritive sources Control Group No nutritional support, placebo support, isocaloric support, isonitrogenous support, or other interventions with a potential effect on HE (ie., lactulose) Outcome Measures Primary Improvement of HE (number of patients improving from HE using definitions of individual trials) Secondary Time to improvement of HE (number of hours/days with HE from the time of randomization to improvement) Survival (number of patients surviving at end of treatment and at max f/up according to trial) Adverse events (number and types of events defined as any untoward medical occurrence in a patient, not necessarily causal with treatment)

25 Branched-Chain Amino Acids For Hepatic Encephalopathy Data Collection and Analysis Trial inclusion and data extraction made independently by two reviewers Statistical heterogeneity tested using random effects and fixed effect models Binary outcomes reported as risk ratios (RR) based on random effects model

26 Branched-Chain Amino Acids For Hepatic Encephalopathy: Results Eleven randomized trials (556 patients) Trial types: BCAA versus carbohydrates, neomycin/lactulose, or isonitrogenous controls Median number of patients in each trial: 55 (range 22 to 75) Follow-up after treatment reported in 4 trials Median 17 days (range 6 to 30 days) Compared to control regimens, BCAA significantly increased the number of patients improving from HE at end of treatment RR 1.31, 95% CI 1.04 to 1.66, 9 trials No evidence of an effect of BCAA on survival RR 1.06, 95% CI 0.98 to 1.14, 8 trials No adverse events (RR 0.97, 95% CI 0.41 to 2.31, 3 trials)

27 Authors' conclusions: No convincing evidence that BCAA had a significant beneficial effect on improvement of HE or survival in patients with HE Small trials with short and most of poor quality Primary analysis showed a significant benefit of BCAA on HE, but significant statistical heterogeneity was present Low methodological quality source of heterogeneity (=bias) Benefits of BCAA on HE only observed when lower quality studies included Effect size and small study bias No significant association between dose or duration and the effect of BCAA

28 How Much Protein: That is the Question?? Grade III to IV hepatic encephalopathy Usually no oral nutrition Upon improvement, individual protein tolerance can be titrated by gradually increasing oral protein intake every three to five days from a baseline of 40 g/day Oral protein not to exceed 70 g/day if pt has hx of hepatic encephalopathy Below 70 g/day rarely necessary, minimum intake should not be lower than 40 g/day to avoid negative nitrogen balance. 1.0g/kg/day protein, depending on degree of muscle wasting BCAA-enriched solutions may benefit protein intolerant (<1g/kg)

29 How Much Protein: That is the Question?? Up to 1.6g/kg/day protein as tolerated Low-grade HE (minimal, I, II) should not be contraindication to adequate protein supply In patients intolerant of a daily intake of 1 g protein/kg, oral BCAA up to 0.25 g/kg may be beneficial to create best possible nitrogen balance BCAAs do not exacerbate encephalopathy It should consider in patients with transjagular intrahepatic port systemic shunt( high incidence for HE)

30 L-ornithine L-asprtate(LOLA) in ALF L-Ornithine L-asprtate(LOLA) acts to stimulate the urea cycle and glutamine synthesis which are important mechanisms in ammonia detoxification, and by that it is considered an ammonia lowering treatment. Many clinical trials found that LOLA improved hepatic encephalopathy better than placebo.

31 Chronic Liver Disease Algorithm content developed by John Anderson, PhD, and Sanford C. Garner, PhD, Updated by Jeanette M. Hasse and Laura E. Matarese, 2002.

32 Clinical manifestation of cirrhosis Severe damage to structure & function of normal cells Inhibits normal blood flow Decrease in # functional hepatocytes Results in portal hypertension & ascites Portal systemic shunting Blood bypasses the liver via shunt, thus bypassing detoxification Toxins remain in circulating blood Neurtoxic substances can precipitate hepatic encephalopathy

33 Chronic liver disease malnourished?? Decreased Absorption Inadequate bile flow Bacterial overgrowth Pancreatic insufficiency Iatrogenic Factors unecessary dietary restrictions Frequent Paracentesis Diuresis (micronutrient losses) Lactulose therapy Decreased Intake Anorexia(altered tast sensation) Early sensation of fullness (ascites) Ascites Altered mental status/encephalopathy Frequent hospitalizations Metabolic Alterations Elevated leptin Increased cholecystokinin Elevated TNF-a

34 Metabolic change in chronic liver disease Hypermetabolic stateenergy -Glucose intolerance in nearly 2/3 of patients with cirrhosis (10- 37% develop diabetes) - Occurs because of insulin resistance in peripheral tissues and decreased in insuline like growth factor. - Hyperinsulinemia, possibly because insulin production increased, hepatic clearance decreased - Fasting hypoglycemia occur after 12 hours fasting due decreased glycogen stores; patients may need small, frequent meals - diminished hepatic and muscle glycogen stores carbohydrate metabolism In fasting state: Plasma level of free fatty acids, glycerol and ketone body Increased Increased lipolysis and mobilization of lipid deposits After meal: Lipid oxidation nt uniformly impaired and plsma clearance not decrease so the patients can utilize fat Essential and polysaturated FA decreased in cirrhotic patients Fat metabolism

35 Metabolic change in chronic liver disease - Increase breakdown and decrease synthesis - Depleted glycogen stores utilize increased fat and muscle protein for fuel even during short-term fasting lead to muscle wasting - Protein catabolism may lead to hyper ammonia Stable cirrhotic patient: Keep positive nitrogenous balance and preserve their lean body mass from protein intake during oral feeding protein - Zinc deficiency is common with cirrhosis. Decreased dietary intake of meats, increased urinary excretion of zinc due to diuretic use, and increased zinc needs have been suggested as causes. Zinc is essential for the function of over 300 enzymes, including those of the urea cycle. - Fat soluble deficiency in patient with cholestatic jaundice - Water soluble vitamine deficiency in alcoholic cirrohosis Mineral and vitamines


37 MNT in chronic Liver Disease Poor Dietary Intake Due to poor appetite, early satiety with ascites Small frequent meals- Aggressive oral supplementation Zinc supplementation Nutrient Malabsorption Due to bile, failure to convert to active forms ADEK supplementation Calcium + D supplementation Folic Acid Supplementation early supplement of thiamine before glucose in alcoholic hepatitis

38 MNT in chronic Liver Disease Calories Most patients are malnourished so supplementing full calories refeeding syndrome Caloric requirement/kg of estimated euvolmic weight Begin with reduced caloric level for the first 2 -3 day Malnourished patients We calculate calories according to euvolemic weight to prevent overestimated energy Patients with ascites 15 to 20 kcl/kgRefeeding risk 25 to 30 kcl /kgMaintainance 30 to 35 cal /kganabolism

39 MNT in in chronic Liver Disease Abnormal Fuel Metabolism Increased perioxidation, gluconeogenesis Bedtime meal to decrease it Protein Deficiency protein catabolism, repeat paracentesis High protein snacks/supplements gms/day

40 MNT in in chronic Liver Disease Standard Guidelines IV with minerals 2gm Na restriction in presence of ascites Do not restrict fluid unless serum Na <120mmol NGT used in pts awaiting transplant TPN should be considered only if contraindication for enteral feeding

41 Treatment of assosciated steatorrhea Fat restricted when steatorrhea is present Medium-chain triglycerides (MCT) can replace some of the fats. They contain only 8-12 carbons:changes their physical characteristics. They are much more water soluble; can be absorbed across the small intestine wall into the blood stream. Mainly, they are transported direct to the liver via the portal vein. They do not bind to fatty acid-binding proteins, are not reesterified to triglycerides, and are not packaged in chylomicrons

42 Nutrition in liver transplanted patients - initiate entral or oral within 12 to 24 hours post operatively In early postoperative phase suffer from hyperglycemia: ----Diabetogenic potential of tacrolimus ----Disturbed glucose metabolism and presence of insulin resistance These patients have negative nitrogen balance up to 28 days post op so they need increase supplementation of protien and amino acids upto 1 to 1.5 g/kg/day with no need for branched chain AA. Postoperative magnesium should be monitored.

43 conclusion Medical nutrition therapy is cornerstone in manging hepatic patients besides other medical treatments

44 References Müller, M. J., Selberg, O. & Böker, K. (1994) Are patients with liver cirrhosis hypermetabolic?. Clin. Nutr. 13: The ESPEN Consensus GroupPlauth, M., Merli, M., Kondrup, J., Weimann, A., Ferenci, P. & Muller, M. J. (1997) ESPEN guidelines for nutrition in liver disease and transplantation. Clin. Nutr. 16: Falck-Ytter, Y., Younossi, Z. M., Marchesini, G. & McCullough, A. J. (2001) Clinical features and natural history of nonalcoholic steatosis syndromes. Semin. Liver Dis. 21: Italian Multicentre Cooperative Project on nutrition in liver cirrhosis (1994) Nutritional status in cirrhosis. J. Hepatol. 21: Marchesini, G., Bianchi, G., Amodio, P., Salerno, F., Merli, M., Panella, C., Loguercio, C., Apolone, G., Niero, M. & Abbiati, R. (2001) Factors associated with poor health- related quality of life of patients with cirrhosis. Gastroenterology 120: Selberg, O., Bottcher, J., Tusch, G., Pichlmayr, R., Henkel, E. & Muller, M. J. (1997) Identification of high- and low-risk patients before liver transplantation: a prospective cohort study of nutritional and metabolic parameters in 150 patients. Hepatology 25: James, J. H., Ziparo, V., Jeppsson, B. & Fischer, J. E. (1979) Hyperammonaemia, plasma amino acid imbalance, and blood-brain amino acid transport: a unified theory of portal-systemic encephalopathy. Lancet 2: Naylor, C. D., ORourke, K., Detsky, A. S. & Baker, J. P. (1989) Parenteral nutrition with branched-chain amino acids in hepatic encephalopathy. A meta-analysis. Gastroenterology 97: Fabbri, A., Magrini, N., Bianchi, G., Zoli, M. & Marchesini, G. (1996) Overview of randomized clinical trials of oral branched-chain amino acid treatment in chronic hepatic encephalopathy. J. Parenter. Enteral Nutr. 20: Als-Nielsen, B., Koretz, R. L., Kjaergard, L. L. & Gluud, C. (2004) Branched-chain amino acids for hepatic encephalopathy (Cochrane review). The Cochrane Library, Issue John Wiley and Sons Chichester, UK. Ishiki, Y., Ohnishi, H., Muto, Y., Matsumoto, K. & Nakamura, T. (1992) Direct evidence that hepatocyte growth factor is a hepatotrophic factor for liver regeneration and has a potent antihepatitis effect in vivo. Hepatology 16: Tomiya, T., Inoue, Y., Yanase, M., Arai, M., Ikeda, H., Tejima, K., Nagashima, K., Nishikawa, T. & Fujiwara, K. (2002) Leucine stimulates the secretion of hepatocyte growth factor by hepatic stellate cells. Biochem. Biophys. Res. Commun. 297: Fenton, J. C., Knight, E. J. & Humpherson, P. L. (1966) Milk-and-cheese diet in portal-systemic encephalopathy. Lancet 1: Bianchi, G. P., Marchesini, G., Fabbri, A., Rondelli, A., Bugianesi, E., Zoli, M. & Pisi, E. (1993) Vegetable versus animal protein diet in cirrhotic patients with chronic encephalopathy. A randomized cross-over comparison. J. Intern. Med. 233: Rossi-Fanelli, F., Riggio, O., Cangiano, C., Cascino, A., De Conciliis, D., Merli, M., Stortoni, M., Giunchi, G. & Capocaccia, L. (1982) Branched-chain amino acids vs. lactulose in the treatment of hepatic coma. A controlled study. Dig. Dis. Sci. 27:

45 References Wahren, J., Denis, J., Desurmont, P., Eriksson, L. S., Escoffier, J. M., Gauthier, A. P., Hagenfeldt, L., Michel, H. & Opolon, P., et al (1983) Is intravenous administration of branched chain amino acids effective in the treatment of hepatic encephalopathy?. A multicenter study. Hepatology 3: Michel, H., Bories, P., Aubin, J. P., Pomier-Layrargues, G., Bauret, P. & Bellet-Herman, H. (1985) Treatment of acute hepatic encephalopathy in cirrhotics with a branched-chain amino acids enriched versus a conventional amino acids mixture. A controlled study of 70 patients. Liver 5: Cerra, F. B., Chung, N. K., Fischer, J. E., Kaplowitz, N., Schiff, E. R., Dienstag, J. L., Bower, R. H., Mabry, C. D., Leevy, C. M. & Kiernan, T. (1985) Disease-specific amino acid infusion (F080) in hepatic encephalopathy: a prospective, randomized, double-blind controlled trial. J. Parenter. Enteral Nutr. 9: Fiaccadori, F., Ghinelli, F., Pedretti, G., Pelosi, G., Sacchini, D., Zeneroli, M. L., Rocchi, E., Gibertini, P. & Ventura, E. (1985) Branched-chain enriched amino acid solutions in the treatment of hepatic encephalopathy: a controlled trial. Ital. J. Gastroenterol. 17:5-10. Strauss, E., dos Santos, W. R., da Silva, E. C., Lacet, C. M., Capacci, M.L.L. & Bernardini, A. P. (1986) Treatment of hepatic encephalopathy: a randomized clinical trial comparing branched chain enriched amino acid solution to oral neomycin. Nutr. Supp. Services 6: Vilstrup, H., Gluud, C., Hardt, F., Kristensen, M., Køler, O., Melgaard, B., Dejgaard, A., Hansen, B. E. & Krintel, J. J., et al (1990) Branched chain enriched amino acids versus glucose treatment of hepatic encephalopathy. A double-blind study of 65 patients with cirrhosis. J. Hepatol. 10: Eriksson, L. S., Persson, A. & Wahren, J. (1982) Branched-chain amino acids in the treatment of chronic hepatic encephalopathy. Gut 23: Sieg, A., Walker, S., Czygan, P., Gärtner, U., Lanzinger-Rossnagel, G., A., S. & Kommerell, B. (1983) Branched-chain amino acid-enriched elemental diet in patients with cirrhosis of the liver. Z. Gastroenterol. 21: Simko, V. (1983) Long-term tolerance of a special amino acid oral formula in patients with advanced liver disease. Nutr. Rep. Int. 27: Horst, D., Grace, N. D., Conn, H. O., Schiff, E., Schencker, S., Viteri, A., Law, D. & Atterbury, C. E. (1984) Comparison of dietary protein with an oral, branched chain-enriched amino acid supplement in chronic portal-systemic encephalopathy. Hepatology 4: Christie, M. L., Sack, D. M., Pomposelli, J. & Horst, H. (1985) Enriched branched-chain amino acid formula vs. a casein-based supplement in the treatment of cirrhosis. J. Parenter. Enteral Nutr. 9: Egberts, E. H., Schomerus, H., Hamster, W. & Jürgens, P. (1985) Branched chain amino acids in the treatment of latent portosystemic encephalopathy. A double- blind placebo-controlled cross-over study. Gastroenterology 88: Fiaccadori, F., Elia, G. F., Lehndorff, H., Merli, M., Pedretti, G., Riggio, O. & Capocaccia, L. (1988) The effect of dietary supplementation with branched-chain amino acids vs. casein in patients with chronic recurrent portal systemic encephalopathy: a controlled trial. Soeters, P. B. Wilson, J.H.P. Meijer, A. J. Holm, E. eds. Advances in Ammonia Metabolism and Hepatic Encephalopathy 1988: Excerpta Medica Amsterdam, The Netherlands.. Swart, G. R., van den Berg, W. O., van Vuure, J. K., Rietveld, D., Wattimena, D. L. & Frenkel, M. (1989) Minimum protein requirements in liver cirrhosis determined by nitrogen balance measurements at three levels of protein intake. Clin. Nutr. 8:

46 References Marchesini, G., Dioguardi, F. S., Bianchi, G. P., Zoli, M., Bellati, G., Roffi, L., Martines, D. & Abbiati, R. & the Italian Multicenter Study Group (1990) Long- term oral branched-chain amino acid treatment in chronic hepatic encephalopathy. A randomized double-blind casein-controlled trial. J. Hepatol. 11: Marchesini, G., Bianchi, G., Merli, M., Amodio, P., Panella, C., Loguercio, C., Rossi Fanelli, F. & Abbiati, R. (2003) Nutritional supplementation with branched- chain amino acids in advanced cirrhosis: a double-blind, randomized trial. Gastroenterology 124: Lieber, C. S. (2000) Alcoholic liver disease: new insights in pathogenesis lead to new treatments. J. Hepatol. 32: Marsano, L. & McClain, C. J. (1991) Nutrition and alcoholic liver disease. J. Parenter. Enteral Nutr. 15: Merli, M., Nicolini, G., Angeloni, S. & Riggio, O. (2002) Malnutrition is a risk factor in cirrhotic patients undergoing surgery. Nutrition 18: Fan, S. T., Lo, C. M., Lai, E. C., Chu, K. M., Liu, C. L. & Wong, J. (1994) Perioperative nutritional support in patients undergoing hepatectomy for hepatocellular carcinoma. N. Engl. J. Med. 331: The San-in Group of Liver Surgery (1997) Long-term oral administration of branched chain amino acids after curative resection of hepatocellular carcinoma: a prospective randomized trial. Br. J. Surg. 84: Poon, R. T., Yu, W. C., Fan, S. T. & Wong, J. (2004) Long-term oral branched chain amino acids in patients undergoing chemoembolization for hepatocellular carcinoma: a randomized trial. Aliment. Pharmacol. Ther. 19: Reilly, J., Mehta, R., Teperman, L., Cemaj, S., Tzakis, A., Yanaga, K., Ritter, P., Rezak, A. & Makowka, L. (1990) Nutritional support after liver transplantation: a randomized prospective study. J. Parenter. Enter Nutr. 14: Bilbao, I., Armadans, L., Lazaro, J. L., Hidalgo, E., Castells, L. & Margarit, C. (2003) Predictive factors for early mortality following liver transplantation. Clin. Transplant. 17: Tietge, U. J., Bahr, M. J., Manns, M. P. & Boker, K. H. (2003) Hepatic amino-acid metabolism in liver cirrhosis and in the long-term course after liver transplantation. Transpl. Int. 16:1-8. Charlton, M. (2003) Branched-chain amino acid-enriched supplements as therapy for liver disease: Rasputin lives. Gastroenterology 124:

47 Thank you

Download ppt "Presented by Faten farid elsayed Nutritional Management of Hepatic patients."

Similar presentations

Ads by Google